Made here.

A pharmaceutical ingredient typically starts as a precursor in one country, gets synthesised in another, and is formulated somewhere else. Every stop adds cost, latency, and dependency on someone else's supply chain.

Making medicine locally is faster to respond when demand shifts. It is easier to audit when quality questions arise. It gives a country agency over the medicines its people depend on.

We built NMT because biosynthesis, done well, lets us do everything in one place — gene design, engineering, fermentation, purification, release. That matters for the economics. It also matters for resilience.